• StenoCare flagged renewed uncertainty in Germany’s medical cannabis reimbursement regime under rules effective July 30.
• Germany’s medical cannabis market is projected at DKK 8.5 billion in 2026, with about 25% tied to statutory reimbursement.
• Dried cannabis flower is no longer eligible for GKV reimbursement, shifting reimbursed demand toward extracts, oils, dronabinol, authorized medicines.
• Dispute centers on a six-month requirement to try a marketing-authorized cannabis medicine before reimbursed extracts or oils for new patients.
• Pharmacies face repayment risk if insurers later reject claims, potentially curbing dispensing until the Health Ministry clarifies interpretation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. StenoCare A/S published the original content used to generate this news brief via Cision (Ref. ID: 202609071005BITN____UKPR__EN_20260907-BIT-7282-0) on September 07, 2026, and is solely responsible for the information contained therein.